Biotech Values

[jq1234]

One of the biq questions that came up during Q&A related to hypersensitivity and management claimed that they've seen a 7% hypersensitivity rate in their trials of Uplyso, which is similar to Cerezyme. Also, the magnitude of the hypersensitivity is apparently similar as well.

This is one reason I like PLX management. Numerically, Uplyso produced better number in quite a few parameters in its trial than from Cerezyme trial both pre and post approval trial. However, PLX never claimed Uplyso is better than Cerezyme or Vpriv because it has not done superiority comparison trial. They always say they are similar. If other companies have a drug like this, you would hear so much about their so called "advantage" over other drugs conference after conference.